1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 dose escalation study of IGM-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-cell malignancies
    Meeting Abstract

    Budde, E.; Gopal, A. K.; Kim, W. S.; Flinn, I. W.; Cheah, C. Y. Y.; Nastoupil, L.; Matasar, M. J.; Diefenbach, C. S.; Gregory, G. P.; Qazi, I.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: Results of an interim analysis
    Meeting Abstract

    Brammer, J. E.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Jacobsen, E. D.; Gritti, G.; Litwak, D.; Cohan, D.; Katz, D. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The outcome of CLL patients according to IGHV mutational status: An Israeli perspective
    Meeting Abstract

    Bronstein, Y.; Levi, S.; Tsuriel, S.; Arbel, Y. S.; Joffe, E.; Herishanu, Y.
    Blood (2021)

    Fulltext@MSK | Save
  • MI-IMMUNE/1801: Lessons from an ongoing, multi-center trial involving biospecimen collection for prospective microbiome and immune profiling in patients undergoing reduced intensity conditioning allogeneic HCT
    Meeting Abstract

    Brooks, E.; Spahn, A.; Waldvogel, S.; Howard, A.; Bar, M.; Bratrude, B.; Chhabra, S.; Clark, W.; Das, S. R.; Horowitz, M. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • PK and PD assessment of BET inhibitor pelabresib (CPI-0610) in patients with relapsed or refractory lymphoma: Findings from a phase 1 study
    Meeting Abstract

    Blum, K. A.; Supko, J. G.; Maris, M.; Flinn, I. W.; Goy, A. H.; Younes, A.; Bobba, S.; Senderowicz, A.; Efuni, S.; Rippley, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Multi-recombinase mouse models of FLT3-driven leukemia identifies distinct trajectories of mutational cooperativity and leukemic transformation
    Meeting Abstract

    Bowman, R. L.; Mishra, T.; Eisman, S. E.; Cai, L.; Xiao, W.; Waarts, M. R.; Sanchez Vela, P.; Fernández-Maestre, I.; Csete, I. S.; Potts, C. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Cost-effectiveness of liposomal cytarabine-daunorubicin (CPX-351) compared to conventional cytarabine-daunorubicin chemotherapy in acute myeloid leukemia
    Meeting Abstract

    Bewersdorf, J. P.; Goshua, G.; Patel, K. K.; Shallis, R. M.; Podoltsev, N.; Huntington, S. F.; Zeidan, A. M.
    Blood (2021)

    Fulltext@MSK | Save
  • A multi-institutional retrospective analysis of T-cell lymphomas with central nervous system relapse
    Meeting Abstract

    Bhansali, R. S.; Ganesan, N.; Stuver, R. N.; Horwitz, S. M.; Wudhikarn, K.; Hwang, S. R.; Bennani, N.; Chavez, J. C.; Sokol, L.; Saeed, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim analysis of the randomized phase 1b/3 study evaluating the safety and efficacy of tazemetostat plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Park, S. I.; Nastoupil, L.; Phillips, T.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Pagel, J. M.; Leonard, J. P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in combination with R-CHOP in patients with previously untreated high-risk diffuse large B-cell lymphoma: Preliminary results from a phase 1/2 trial
    Meeting Abstract

    Belada, D.; Christensen, J. H.; Drott, K.; Snauwaert, S.; Brody, J.; Narkhede, M.; Offner, F.; Elliot, B.; Liu, T.; Stirner, M. C.; more...
    Blood (2021)

    Fulltext@MSK | Save